CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
Omega-3 Fatty Acid +1 moredrug
Likely dose
Omega-3 Fatty Acid 325mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00644423
NCT00644423N/ACompleted
CompareCT.gov

Omega-3 Fatty Acids and PTSD

Durham VA Medical Center·interventional·Posted Mar 26, 2008·Updated Aug 20, 2019

In Brief

A clinical study evaluating Omega-3 Fatty Acid and Placebo for Posttraumatic Stress Disorder. Completed, enrolled 18 participants across 1 site.

Detailed Summary

An increasing literature shows that omega-3 fatty acids provide numerous health benefits, including a variety of psychiatric symptoms and disorders including stress, anxiety, cognitive impairment, mood disorders (major depression and bipolar disorder) and schizophrenia. Omega-3 fatty acids may additionally represent a promising treatment strategy in patients with PTSD. Moreover, given its beneficial cardiovascular effects, adjunctive omega-3 fatty acids may also benefit the general health status of these veterans, who frequently present with a variety of comorbid medical disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosttraumatic Stress Disorder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2008
Enrollment StartSep 22, 2008
Primary CompletionJul 15, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.3 years ago

Interventions

Omega-3 Fatty Aciddrug

One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)

Placebodrug

Matching Placebo